JP2015506376A5 - - Google Patents

Download PDF

Info

Publication number
JP2015506376A5
JP2015506376A5 JP2014555805A JP2014555805A JP2015506376A5 JP 2015506376 A5 JP2015506376 A5 JP 2015506376A5 JP 2014555805 A JP2014555805 A JP 2014555805A JP 2014555805 A JP2014555805 A JP 2014555805A JP 2015506376 A5 JP2015506376 A5 JP 2015506376A5
Authority
JP
Japan
Prior art keywords
pharmaceutical formulation
patient
cancer
administering
cdk8
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014555805A
Other languages
English (en)
Japanese (ja)
Other versions
JP6193268B2 (ja
JP2015506376A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/024515 external-priority patent/WO2013116786A1/en
Publication of JP2015506376A publication Critical patent/JP2015506376A/ja
Publication of JP2015506376A5 publication Critical patent/JP2015506376A5/ja
Application granted granted Critical
Publication of JP6193268B2 publication Critical patent/JP6193268B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014555805A 2012-02-02 2013-02-01 Cdk8/cdk19選択的阻害剤、ならびに癌のための抗転移および化学防御の方法におけるそれらの使用 Expired - Fee Related JP6193268B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261594023P 2012-02-02 2012-02-02
US61/594,023 2012-02-02
US201261673419P 2012-07-19 2012-07-19
US61/673,419 2012-07-19
PCT/US2013/024515 WO2013116786A1 (en) 2012-02-02 2013-02-01 Cdk8/cdk19 selective inhibitors and their use in anti-metastatic and chemopreventative methods for cancer

Publications (3)

Publication Number Publication Date
JP2015506376A JP2015506376A (ja) 2015-03-02
JP2015506376A5 true JP2015506376A5 (https=) 2016-05-19
JP6193268B2 JP6193268B2 (ja) 2017-09-06

Family

ID=47716178

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014555805A Expired - Fee Related JP6193268B2 (ja) 2012-02-02 2013-02-01 Cdk8/cdk19選択的阻害剤、ならびに癌のための抗転移および化学防御の方法におけるそれらの使用

Country Status (16)

Country Link
US (2) US9321737B2 (https=)
EP (2) EP2809324B1 (https=)
JP (1) JP6193268B2 (https=)
KR (1) KR20150023223A (https=)
CN (1) CN104363913B (https=)
AU (1) AU2013214783B2 (https=)
BR (1) BR112014019052A8 (https=)
CL (1) CL2014002062A1 (https=)
CO (1) CO7151516A2 (https=)
EA (2) EA028595B1 (https=)
GE (2) GEP20186818B (https=)
MY (1) MY165446A (https=)
PH (1) PH12014501862A1 (https=)
SG (1) SG11201404596UA (https=)
UA (1) UA117342C2 (https=)
WO (1) WO2013116786A1 (https=)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA027809B1 (ru) * 2012-07-27 2017-09-29 Биоген Айдек Ма Инк. Соединения, которые являются s1p-модулирующими агентами и/или atx-модулирующими агентами
EP2888232A1 (en) * 2012-08-23 2015-07-01 F. Hoffmann-La Roche AG Novel phenyl-pyridine/pyrazine amides for the treatment of cancer
EP2914266B1 (en) 2012-11-01 2019-06-19 University of South Carolina Cdk8/cdk19 selective inhibitors for use in a method for treating prostate cancer
EP2961409A1 (en) * 2013-02-26 2016-01-06 Senex Biotechnology, Inc. Inhibitors of cdk8/19 for use in treating estrogen receptor positive breast cancer
SG11201605178WA (en) 2013-12-24 2016-07-28 Harvard College Cortistatin analogues and syntheses and uses thereof
EP3205645B1 (en) * 2014-04-18 2019-10-23 Takeda Pharmaceutical Company Limited Heterocyclic compound
WO2016018511A2 (en) * 2014-06-10 2016-02-04 University Of South Carolina Methods and compositions for treatment of her-positive cancers
US20210322651A1 (en) 2014-12-18 2021-10-21 Senex Biotechnology, Inc. Suppression of neointimal formation following vascular surgeru using cdk8 inhibitors
WO2016182932A1 (en) 2015-05-08 2016-11-17 President And Fellows Of Harvard College Cortistatin analogues, syntheses, and uses thereof
CN107847763A (zh) * 2015-05-08 2018-03-27 哈佛学院院长等 靶向选择适合于用皮质抑素衍生物治疗的患者
WO2017004411A1 (en) 2015-07-01 2017-01-05 President And Fellows Of Harvard College Cortistatin analogues and syntheses and uses thereof
MX390651B (es) 2015-11-03 2025-03-21 Apriligen Inc Compuestos para el tratamiento de trastornos hipoproliferativos
WO2017091836A1 (en) * 2015-11-25 2017-06-01 University Of South Carolina Enhancement of cytarabine activity by inhibiting cdk8/19
JP7198489B2 (ja) * 2016-03-23 2023-01-04 国立大学法人 岡山大学 リン酸化sarm1、抗体、sarm1リン酸化阻害剤、神経変性疾患の予防又は治療薬、スクリーニング方法、sarm1改変体及び使用
US11285144B2 (en) 2016-08-03 2022-03-29 The Broad Institute, Inc. Use of CDK8 inhibitors to treat diseases of inflammation and autoimmunity
US11578067B2 (en) * 2017-01-30 2023-02-14 Kyoto University Compound, and method for producing regulatory T cells
WO2018151633A1 (ru) * 2017-02-20 2018-08-23 Закрытое Акционерное Общество "Биокад" Способы получения производных 4-(((нафталин-2-ил)алкил)амино)хинозалин-6-карбонитрилов
US20220040179A1 (en) * 2017-02-23 2022-02-10 University Of South Carolina Use of cdk8/19 inhibitors for treatment of established colon cancer hepatic metastasis
EP3591040A4 (en) 2017-03-03 2020-11-11 Kyoto University METHOD OF PRODUCTION OF PANCREATIC PROGENITOR CELLS
WO2018186366A1 (ja) * 2017-04-03 2018-10-11 京都薬品工業株式会社 新規サイクリン依存性キナーゼ8及び/又は19阻害剤
RU2641001C1 (ru) * 2017-04-03 2018-01-15 Закрытое Акционерное Общество "Биокад" Соли 4-((2-(6-(4-метилпиперазин-1-карбонил)нафталин-2-ил)этил)амино)хиназолин-6-карбонитрила и фармацевтическая композиция
JP7392954B2 (ja) * 2017-09-18 2023-12-06 シーゼット・バイオハブ・エスエフ・リミテッド・ライアビリティ・カンパニー トリプルネガティブ乳癌の治療方法
EP3691642B1 (en) 2017-10-02 2024-03-06 Boehringer Ingelheim International GmbH [1,6]naphthyridine compounds and derivatives as cdk8/cdk19 inhibitors
RU2763347C2 (ru) * 2018-03-01 2021-12-28 Закрытое Акционерное Общество "Биокад" Новые ингибиторы cdk8/19
US12281080B2 (en) 2018-08-21 2025-04-22 University Of South Carolina Quinoline-based compounds and methods of inhibiting CDK8/19
US11014906B2 (en) 2018-08-21 2021-05-25 University Of South Carolina Quinoline-based compounds and methods of inhibiting CDK8/19
CA3128377A1 (en) 2019-02-01 2020-08-06 University Of South Carolina Bicyclic pyridine compositions and methods of using the same for cancer therapy
EP4249587A4 (en) 2020-11-20 2025-02-19 Orizuru Therapeutics, Inc. RIPENING AGENT
WO2022172960A1 (ja) 2021-02-09 2022-08-18 オリヅルセラピューティクス株式会社 成熟化剤
US20240180921A1 (en) * 2021-03-25 2024-06-06 University Of South Carolina Cdk8/19 inhibitors for the treatment of cytokine storm
US20240400993A1 (en) 2021-09-27 2024-12-05 Kyoto University Method for producing t cell
CN118591619A (zh) 2021-11-24 2024-09-03 雷格细胞股份有限公司 人诱导性调节性t细胞及其制作方法
US20250352578A1 (en) 2021-11-24 2025-11-20 Regcell Co., Ltd. Pharmaceutical composition for treating or preventing t cell-related disorders
US20250230411A1 (en) 2022-03-23 2025-07-17 Kyoto University Method for producing regulatory t cells
CN119072542A (zh) 2022-04-25 2024-12-03 千纸鹤治疗公司 具有alk5抑制活性和cdk8/19抑制活性的促熟剂
EP4556555A1 (en) 2022-07-14 2025-05-21 Orizuru Therapeutics, Inc. Fibrin gel sheet for cell transplantation
JPWO2024071010A1 (https=) 2022-09-26 2024-04-04
EP4596684A1 (en) 2022-09-26 2025-08-06 Regcell Co., Ltd. Induced regulatory t cells containing chimeric antigen receptor (car)
EP4663195A1 (en) 2023-02-08 2025-12-17 Regcell Co., Ltd. Pharmaceutical composition for treating or preventing pemphigus
WO2024204553A1 (ja) 2023-03-29 2024-10-03 レグセル株式会社 ヒト誘導性制御性t細胞およびその作製方法、およびt細胞関連疾患を治療または予防するための医薬組成物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6046206A (en) * 1995-06-07 2000-04-04 Cell Pathways, Inc. Method of treating a patient having a precancerous lesions with amide quinazoline derivatives
NZ503788A (en) * 1997-10-27 2002-11-26 Agouron Pharma 4-aminothiazole derivatives and their use as inhibitors of cyclin-dependent kinases
US6440959B1 (en) * 1999-04-21 2002-08-27 Hoffman-La Roche Inc. Pyrazolobenzodiazepines
US20040180848A1 (en) 2003-03-10 2004-09-16 Fesik Stephen W. Method of killing cancer cells
US20040180844A1 (en) 2003-03-10 2004-09-16 Fesik Stephen W. Method of killing cancer cells
MXPA05010824A (es) * 2003-04-10 2005-12-05 Pfizer Compuestos biciclicos como antagonistas del receptor nr2b.
AU2007249762A1 (en) * 2006-05-15 2007-11-22 Senex Biotechnology, Inc Identification of CDKI pathway inhibitors
US8598344B2 (en) 2009-11-30 2013-12-03 Senex Biotechnology CDKI pathway inhibitors and uses thereof

Similar Documents

Publication Publication Date Title
JP2015506376A5 (https=)
JP2016508134A5 (https=)
JP2014532647A5 (https=)
JP2015523397A5 (https=)
JP2017518302A5 (https=)
RU2014120792A (ru) Способ лечения стромальных опухолей желудочно-кишечного тракта
JP2016501221A5 (https=)
EA201100971A1 (ru) Производные пиримидининдола для лечения злокачественного новообразования
RU2017105353A (ru) Соединения
JP2010525056A5 (https=)
JP2016513640A5 (https=)
EA201391263A1 (ru) Комбинированные терапии гематологических опухолей
JP2013506674A5 (https=)
RU2017112747A (ru) Фармацевтические композиции, содержащие декстрометорфановое соединение и хинидин для лечения возбуждения при деменции
JP2016522254A5 (https=)
JP2015503596A5 (https=)
JP2019505529A5 (https=)
JP2019501879A5 (https=)
RU2014139955A (ru) Прокаспазная комбинированная терапия при глиобластоме
JP2015522018A5 (https=)
EP3720560A1 (en) Methods of treating cancer with plk4 inhibitors
JP2013544892A5 (https=)
JP2024535913A (ja) Kras変異を有するがん患者の治療
RU2015101702A (ru) Фармацевтически активные соединения
EA201270298A1 (ru) Способ лечения злокачественной опухоли